Kainate Receptor Antagonists
| Cat. No. | Product Name / Activity |
|---|---|
| 2728 | ACET |
| Potent kainate antagonist; displays selectivity for GluK1-containing receptors | |
| 0190 | CNQX |
| Potent and selective non-NMDA iGluR antagonist | |
| 1045 | CNQX disodium salt |
| Potent non-NMDA iGluR antagonist; more water soluble form of CNQX (Cat. No. 0190) | |
| 0189 | DNQX |
| Selective non-NMDA iGluR antagonist | |
| 2312 | DNQX disodium salt |
| Selective non-NMDA iGluR antagonist; water-soluble salt of DNQX (Cat. No. 0189) | |
| 0845 | Evans Blue tetrasodium salt |
| Non-NMDA iGluR antagonist; P2X antagonist; also inhibits L-glutamate uptake into synaptic vesicles | |
| 2555 | GYKI 53655 hydrochloride |
| Non-competitive non-NMDA iGluR antagonist | |
| 5032 | Talampanel |
| Non-competitive non-NMDA iGluR antagonist | |
| 3620 | Topiramate |
| GluK1 antagonist; inhibits carbonic anhydrase (CA) II and IV; also positive allosteric modulator of GABAA receptors | |
| 2078 | UBP 296 |
| Potent and selective kainate antagonist; selective for GluK1-containing receptors | |
| 1766 | UBP 301 |
| Kainate antagonist | |
| 2079 | UBP 302 |
| Potent and selective kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078) | |
| 3621 | UBP 310 |
| GluK1-selective kainate antagonist | |
| 2345 | ZK 200775 |
| Competitive non-NMDA iGluR antagonist |
Highlights around 500 products for ion channel research.
Request copyRequest PDF
Our Pain guide highlights over 280 products for Pain research.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDF
Written by Alsa Pitkänen and Xavier Ekolle Ndode-Ekane, this poster summarizes current knowledge about how epilepsy develops.
Request copyDownload PDFWritten by Clea Warburton and Zafar Bashir
Our Learning and Memory poster gives an overview of the cellular mechanisms underlying recognition memory and its links to long-term depression.
Request copyDownload PDFWritten by Grant D. Nicol and Michael R. Vasko
Our Peripheral Sensitization poster gives a summary of the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDFWritten by Justin M. Saunders and Javier González-Maeso
Our Schizophrenia poster highlights the targets and pathways representing the most promising strategies to pursue for novel drug development.
Request copyDownload PDF